Taiwanese vaccine maker Adimmune Corp (國光生技) yesterday said it has received approval from the Chinese government for it to start phase three clinical trials of its flu vaccine in China, enabling it to enter the market next year.
The company plans to launch the vaccine immediately after receiving Chinese approval in the first half of next year, company vice president Simon Kao (高聖凱) said.
The company expects to sell less than 1 million vials of vaccine in China next year, but the volume should increase to between 3 million and 5 million vials in 2016, accounting for 10 percent of the market, Kao said.
There are currently 10 companies making flu vaccines in 0.5cc vials, and nine making 0.25cc vials. Adimmune is capable of making vaccines in both sizes, Kao said.
Flu vaccine in China is priced between 10 yuan and 60 yuan (US$1.65 and US$9.85) per vial, while the average price of Adimmune’s will be between 50 yuan and 60 yuan, Kao said.
The company sells 1.5 million vials of flu vaccine in Taiwan at between NT$100 to NT$150 each, it said, adding that domestic sales of the vaccine would account for 40 percent of its revenue this year.
Thanks to the Cross-strait Cooperation Agreement on Medicine and Public Health Affairs (兩岸醫藥衛生合作協議), the company spent only three years to get the green light to start the phase three trials, shorter than five to six years for other companies, Kao said.
“We will be the first company to launch a medical product in China without building a plant there,” chairman Steve Chan (詹啟賢) said.
Meanwhile, Chan said Adimmune’s vaccine for H7N9 avian influenza will complete phase one clinical trails by January and phase two clinical trials by June.
From January through last month, the company posted revenue of NT$273.8 million (US$9.32 million), up 18.23 percent from NT$231.57 million a year ago, as sales to its partner, Dutch-based Crucell, rose to 370g from 200g last year, chief financial officer Vic Chang (張哲瑋) said.
Sales to Crucell, which account for 60 percent of the company’s revenue this year, are expected to increase next year as the company started to provide about 75g to 100g adjuvants for curing hepatitis A, which are twice as expensive as its flu vaccine, Chang said.
Adimmune is likely to remain in the red this year, he said.
The company reported losses of NT$309.25 million in the first half of the year, compared with losses of NT$284.74 million a year ago.
Adimmune‘s shares rose 6.07 percent to NT$47.15 yesterday.
UNCERTAINTIES: Exports surged 34.1% and private investment grew 7.03% to outpace expectations in the first half, although US tariffs could stall momentum The Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) yesterday raised its GDP growth forecast to 3.05 percent this year on a robust first-half performance, but warned that US tariff threats and external uncertainty could stall momentum in the second half of the year. “The first half proved exceptionally strong, allowing room for optimism,” CIER president Lien Hsien-ming (連賢明) said. “But the growth momentum may slow moving forward due to US tariffs.” The tariff threat poses definite downside risks, although the scale of the impact remains unclear given the unpredictability of US President Donald Trump’s policies, Lien said. Despite the headwinds, Taiwan is likely
When Lika Megreladze was a child, life in her native western Georgian region of Guria revolved around tea. Her mother worked for decades as a scientist at the Soviet Union’s Institute of Tea and Subtropical Crops in the village of Anaseuli, Georgia, perfecting cultivation methods for a Georgian tea industry that supplied the bulk of the vast communist state’s brews. “When I was a child, this was only my mum’s workplace. Only later I realized that it was something big,” she said. Now, the institute lies abandoned. Yellowed papers are strewn around its decaying corridors, and a statue of Soviet founder Vladimir Lenin
READY TO BUY: Shortly after Nvidia announced the approval, Chinese firms scrambled to order the H20 GPUs, which the company must send to the US government for approval Nvidia Corp chief executive officer Jensen Huang (黃仁勳) late on Monday said the technology giant has won approval from US President Donald Trump’s administration to sell its advanced H20 graphics processing units (GPUs) used to develop artificial intelligence (AI) to China. The news came in a company blog post late on Monday and Huang also spoke about the coup on China’s state-run China Global Television Network in remarks shown on X. “The US government has assured Nvidia that licenses will be granted, and Nvidia hopes to start deliveries soon,” the post said. “Today, I’m announcing that the US government has approved for us
UNIFYING OPPOSITION: Numerous companies have registered complaints over the potential levies, bringing together rival automakers in voicing their reservations US President Donald Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two weeks, ramping up his push to reshape the US’ standing in the global trading system by penalizing purchases from abroad. Administration officials could release details of Trump’s planned 50 percent duty on copper in the days before they are set to take effect on Friday next week, a person familiar with the matter said. That is the same date Trump’s “reciprocal” levies on products from more than 100 nations are slated to begin. Trump on Tuesday said that he is likely to impose tariffs